Genetic Testing and Motivational Counseling for FH

Medication Adherence Clinical Trial

— GENMOTIV-FH  

Official title:

Impact of Genetic Testing and Motivational Counseling on the Adherence to Healthy Lifestyle and Hypolipidemic Therapy and Efficiency of Cascade Screening in Patients With Familial Hypercholesterolemia (GENMOTIV-FH)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04656028
• Other study ID #: 08-03/19
• Status: Recruiting
• Phase: N/A
• Start date: June 15, 2020
• Est. completion date: March 30, 2025

Study information

• Verified date: November 2023
• Source: National Medical Research Center for Therapy and Preventive Medicine
• Contact: Alexandra Ershova, MD, PhD
• Phone: +79165598536
• Email: alersh[@]mail.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH). However, the effectiveness of treatment of FH patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. The aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with FH.

Description:

There are several tasks of the study: 1. To assess the effect of knowledge of patients with FH about the result of their FH genetic testing on the adherence to a healthy lifestyle and hypolipidemic therapy. 2. To assess the impact of knowledge of patients with FH about the result of their FH genetic testing on the effectiveness of cascade screening. 3. To assess the influence of motivational counseling of patients with FH on the adherence to a healthy lifestyle and hypolipidemic therapy. 4. To assess the impact of motivational counseling of patients with FH on the effectiveness of cascade screening.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: March 30, 2025
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Probable or definite diagnosis of FH according to the Dutch criteria (6 points or more);
• Signed informed consent;

Exclusion Criteria:

• Pregnancy or lactation at the time of enrollment
• Established active severe infectious disease or severe hematologic, metabolic, gastrointestinal or endocrine dysfunctions (for example, uncontrolled thyroid dysfunction or uncontrolled diabetes mellitus) in the opinion of the investigator
• Active liver disease
• Estimated GFR= 30 ml / min / 1.73m2
• Any other conditions at Visit 1 that, according to the investigator's opinion, render the patient ineligible for inclusion in the study, may interfere with the patient's participation in the study or patient's completion of the study.

Related Conditions & MeSH terms

• Adherence
• Adherence, Medication
• Adherence, Patient
• Apolipoprotein B-100, Familial Defective
• Arthrogryposis
• Compliance
• Familial Hypercholesterolemia
• Familial Hypercholesterolemia - Heterozygous
• Familial Hypercholesterolemia With Hyperlipemia
• Genetic Testing
• Hypercholesterolemia
• Hypercholesterolemia, Autosomal Dominant
• Hypercholesterolemia, Autosomal Dominant, 3
• Hypercholesterolemia, Autosomal Dominant, Type B
• Hypercholesterolemia, Familial
• Hypercholesterolemia, Familial, 1
• Hypercholesterolemia, Familial, 2
• Hypercholesterolemia, Familial, 3
• Hypercholesterolemia, Familial, 4
• Hypercholesterolemia, Familial, 4, Autosomal Recessive
• Hyperlipidemias
• Hyperlipoproteinemia Type II
• Hyperlipoproteinemia Type III
• Hyperlipoproteinemias
• Medication Adherence
• Motivational Interviewing
• Patient Adherence
• Patient Compliance
• Therapeutic Adherence
• Therapeutic Adherence and Compliance
• Treatment Adherence
• Treatment Adherence and Compliance

Intervention

Genetic:
• Genetic Testing
DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database <0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).

Behavioral:
• Motivational Counseling
Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits. The goals of motivational counseling: Increasing motivation for a healthy lifestyle; Increasing adherence to treatment; Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling.

Diagnostic Test:
• Lipid analysis
Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.

Other:
• Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)
All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
• Visit 1
Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling. Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is = 7 days.
• Visit 2
Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2. Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is = 7 days
• Visit 3
Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is = 7 days.
• Visit 4
Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is = 7 days.

Locations

Country	Name	City	State
Russian Federation	National Medical Research Centre for Therapy and Preventive Medicine of the Ministry of Health of Russia	Moscow

Sponsors (2)

Lead Sponsor	Collaborator
National Medical Research Center for Therapy and Preventive Medicine	Moscow State University of Medicine and Dentistry

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the proportion of people who have reached the target level of LDL-Cholesterol	Change in the proportion of people who have reached the target level of LDL-Cholesterol (target values of LDL-C according to the ESC Dislipidaemia Guidelines 2019)	3 months
Primary	Change in the number of relatives who underwent cascade screening	Change in the number of relatives who underwent cascade screening (% of relatives out of all available relatives. Available relatives are those who are alive and live in the region of where the study is conducted (Moscow and Moscow region)	3 months
Primary	Change in the proportion of people adhering to drug therapy	Change in the proportion of people adhering to drug therapy according to the questionnaire MARS-5	3 months
Primary	Change in the proportion of people adhering to the recommended physical activity	Change in the proportion of people adhering to the recommended physical activity (according to the Global Physical Activity Questionnaire (GPAQ))	3 months
Primary	Change in the proportion of individuals adhering to the recommended dietary recommendations	Change in the proportion of individuals adhering to the recommended dietary recommendations (according to 24-hour Dietary Recall and Food Frequency Questionnaires)	3 months
Secondary	Change in the proportion of people who have reached the target level of LDL-Cholesterol	Change in the proportion of people who have reached the target level of LDL-Cholesterol (target values of LDL-C according to the ESC Dislipidaemia Guidelines 2019)	15 months
Secondary	Change in the number of relatives who underwent cascade screening	Change in the number of relatives who underwent cascade screening (% of relatives out of all available relatives. Available relatives are those who are alive and live in the region of where the study is conducted (Moscow and Moscow region)	15 months
Secondary	Change in the proportion of people adhering to drug therapy	Change in the proportion of people adhering to drug therapy according to the questionnaire MARS-5	15 months
Secondary	Change in the proportion of people adhering to the recommended physical activity	Change in the proportion of people adhering to the recommended physical activity (according to the Global Physical Activity Questionnaire (GPAQ))	15 months
Secondary	Change in the proportion of individuals adhering to the recommended dietary recommendations	Change in the proportion of individuals adhering to the recommended dietary recommendations (according to 24-hour Dietary Recall and Food Frequency Questionnaires)	15 months